'Mad Money' Lightning Round: United Rentals Is Really Good
at The Street - 13 mins ago
Cramer prefers HollyFrontier to CVR Refining and says wait a bit on GW Pharmaceuticals.
Jim Cramer's 'Mad Money' Recap: Nerds Rule
at The Street - Thu Apr 24, 7:19PM CDT
Uncool companies left for dead last quarter are making a comeback, Cramer says.
Final Glance: Biotechnology companies
AP - Thu Apr 24, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Caterpillar and D.R. Horton are big market movers
AP - Thu Apr 24, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...
Midday Glance: Biotechnology companies
AP - Thu Apr 24, 12:28PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Celgene Earnings Grow Year Over Year in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 12:27PM CDT
Product sales increased at Celgene (CELG) in the quarter.
Oncology Drug Growth Fuels Celgene's Q1 Profit Higher by 22%
Sean Williams, The Motley Fool - Motley Fool - Thu Apr 24, 11:21AM CDT
Cancer-focused biopharmaceutical behemoth Celgene today reported steady growth in many of its key products and a higher adjusted profit in the first quarter despite a clear-cut rise in expenses. For the quarter, Celgene delivered total revenue...
June 6th Options Now Available For Celgene (CELG)
at The Street - Thu Apr 24, 11:14AM CDT
Investors in Celgene Corp. saw new options begin trading today, for the June 6th expiration.
Jim Cramer Breaks Down Apple (AAPL), Caterpillar (CAT) and American Airlines Group's (AAL) Earnings
at The Street - Thu Apr 24, 11:04AM CDT
TheStreet's Jim Cramer breaks down Apple (AAPL), Caterpillar (CAT) and American Airlines Group's (AAL) earnings.
Alexion, Celgene Report Contrasting Q1 Earnings
at Investor's Business Daily - Thu Apr 24, 10:39AM CDT
Big-cap biotech Alexion Pharmaceuticals (ALXN) beat Q1 estimates and raised its full-year-earnings guidance Thursday, sending the stock up 3% in morning trading on the stock market. Fellow biotech giant Celgene (CELG) missed, however. Alexion...
Jim Cramer's Stop Trading: CELG
at The Street - Thu Apr 24, 10:06AM CDT
Celgene is a very cheap stock but investors aren't willing to buy it, Cramer says.
Early Glance: Biotechnology companies
AP - Thu Apr 24, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Stock Market News for April 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 9:06AM CDT
Benchmarks ended lower on Wednesday following disappointing corporate results and economic data
Today's Top Health Care Stocks to Watch: AstraZeneca plc, Alexion Pharmaceuticals, Celgene Corporati
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 7:39AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AstraZeneca , Alexion Pharmaceuticals , Celgene Corporation and Novartis AG . Alexion Pharmaceuticals easily beats earnings estimates Alexion...
Celgene Reports First Quarter 2014 Operating and Financial Results
Business Wire - Thu Apr 24, 6:33AM CDT
--Late-stage product acquisition of GED-0301 from Nogra Pharma Ltd
Celgene Acquires Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders
Business Wire - Thu Apr 24, 6:32AM CDT
--- Phase III Program for Crohn's Disease Targeted to Begin by Year-End 2014
3 Reasons Celgene Will Bounce Back This Year
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
The market's up-and-down performance in 2014 has taken its toll on the biotech sector, and big biotech Celgene hasn't been immune to the sectorwide slump. Celgene's shares have fallen by double-digit percentages since the year kicked off, even as...
Here's What This Billion-Dollar Financial Advisor Has Been Buying and Selling
Selena Maranjian, The Motley Fool - Motley Fool - Wed Apr 23, 4:15PM CDT
Every quarter, many money managers have to disclose what they've bought and sold, via 13F filings. Their latest moves can shine a bright light on smart stock picks. Today let's look at investment advisory firm Douglass Winthrop Advisors. It's of...